Orion Pharma Partners with Qilu Pharma for Pembrolizumab Biosimilar in Europe

Key Facts

1Orion Pharma and Qilu Pharma Europe entered into an agreement to commercialize an intravenous pembrolizumab biosimilar in Europe.

2Pembrolizumab is an immune checkpoint inhibitor used in the treatment of various types of cancer.

Orion Pharma and Qilu Pharma Europe entered into an agreement to commercialize an intravenous pembrolizumab biosimilar in the European market, GlobeNewswire reported. Under the terms of the deal, Orion Pharma secured exclusive rights for the distribution, marketing, and sale of the biosimilar, which is an immune checkpoint inhibitor used to treat various types of cancer.

ORINY closed at $45.77 on October 5, 2026, with the stock trading between a low of $44.87 and a high of $45.77 during that session. The partnership aims to expand Orion's oncology portfolio, with Qilu Pharma supplying the product in exchange for a share of profits and milestone payments related to development and regulatory approvals.